

**NIOX MINO™ - a new first-of-a-kind hand-held analyzer of inflammation in asthma - winner product in the 2005 Medical Design Excellence Awards (MDEA) competition.**

NIOX MINO™, hand-held F<sub>ENO</sub> analyzer, has been selected as a winner in the 2005 Medical Design Excellence Awards (MDEA) competition in the US, the premier awards program for the medical technology community. This is the only award program that exclusively recognizes contributions and advances in the design of medical technology products.

NIOX MINO™ is a new first-of-a-kind hand-held analyzer of inflammation in asthma patients. The device measures exhaled nitric oxide, a responsive non-invasive biomarker of airway inflammation.

“We are proud to receive this award, exhaled nitric oxide as a biomarker of inflammation shows great promise in the diagnosis of asthma and in monitoring the patient’s response to anti-inflammatory therapy. NIOX MINO™ now allows exhaled nitric oxide measurement in routine practice, clinical trials on a broad scale and can be used all the way in to the patients’ home” says Thomas Almesjö, CEO of Aerocrine AB.

Special attention has been given to make the device user-friendly. Great efforts have been made in order to give the device a friendly and “soft” look. The nitric oxide measurement procedure should be playful and stimulating rather than technical and demanding.

“The collaboration with our partners, - Ergonomidesign for the exterior design and user interface, - Teleca for the technical design has been crucial for the successful development of NIOX MINO”, says Mats Carlson, VP Development at Aerocrine.

Aerocrine AB is a clinically based medical technology company that leads the way in the development of devices for monitoring inflammation through the measurement of gaseous markers. The company was founded in 1997 by scientists from the prestigious Karolinska Institute in Sweden and has its headquarters in Solna, Stockholm. The founders were the first to identify nitric oxide (NO) as a marker of inflammation. Today, this strong scientific heritage is supported by an international network of clinical advisors as well as an experienced and efficient management team, which is bringing innovative ideas into clinical practice. Aerocrine holds a comprehensive patent portfolio, including eleven approved patents in the USA, with patents pending.

Contacts: [www.aerocrine.com](http://www.aerocrine.com)    [www.nioxmino.com](http://www.nioxmino.com)

e-mail: [info@aerocrine.com](mailto:info@aerocrine.com)

Thomas Almesjö  
President & CEO

[thomas.almesjo@aerocrine.com](mailto:thomas.almesjo@aerocrine.com)  
Mobile: +46 70 6290782

Mats Carlson  
VP Development

[mats.carlson@aerocrine.com](mailto:mats.carlson@aerocrine.com)  
Mobile: +46 70 5348989